Additionally, both pharmacological inhibition and genetic ablation of various TKs including Abelson (Abl), platelet-derived growth factor receptors (PDGFR)α, and fused-in sarcoma (Src) have been shown to reduce concentrations of amyloid-beta (Aβ) and phospho-tau (pTau) in preclinical models of AD and PD (Dhawan and Combs, 2012; Javidnia et al., 2017; Fowler et al., 2019). The gene discussed is MAPT; the disease is Parkinson disease.